Gilead vs. Cipla: Consent Judgment Upholds Biktarvy HIV Patents in Landmark Case

Case Overview

The Parties

Note: Lupin Limited and Laurus Labs Limited were also named as additional defendants in the broader litigation, reflecting a multi-front ANDA litigation strategy.

Patents at Issue

This landmark case involved four key patents protecting Gilead’s HIV treatment Biktarvy®:

• • US 9,708,342 — Composition and methods related to bictegravir sodium.
• • US 10,385,067 — Further compositions related to bictegravir sodium combination.
• • US 10,548,846 — Additional method claims for bictegravir combinations.
• • US 11,744,802 — Broader claims covering bictegravir and its combinations.

Litigation Timeline & Procedural History

Filed on May 9, 2022, the action proceeded over 1,246 days — approximately three and a half years — before closing on October 6, 2025. The extended duration is characteristic of complex Hatch-Waxman ANDA litigation, where multiple defendants, broad patent portfolios, and extensive discovery timelines routinely extend proceedings beyond initial projections.

Venue in the District of Delaware reflects deliberate strategic choice by Gilead. Delaware remains the dominant forum for pharmaceutical patent litigation, offering a specialized judiciary experienced in Hatch-Waxman disputes. The case was presided over by Chief Judge Maryellen Noreika, a well-regarded jurist known for efficient case management in IP matters.

The multi-defendant structure — naming Lupin Limited, Cipla Limited, and Laurus Labs Limited — suggests coordinated ANDA filings targeting Biktarvy®, a common industry dynamic where multiple generic entrants file near-simultaneously to trigger the 30-month litigation stay and compete for 180-day first-filer exclusivity.

The Verdict & Legal Analysis

Outcome: Consent Judgment Favoring Gilead

The case resolved via consent judgment — a court-ordered agreement jointly stipulated by Gilead and Cipla. The judgment, entered under Case Document 367, establishes several consequential legal determinations:

• Patent Validity Affirmed: The claims of U.S. Patent Nos. 9,708,342 and 10,385,067 are declared valid and enforceable.
• Permanent Injunction Granted: Cipla and its affiliates are enjoined from making, using, selling, or importing the accused generic formulation until a privately agreed date.
• Claims Dismissed Without Prejudice: All affirmative defenses, counterclaims, and invalidity challenges are dismissed without prejudice.
• Each Party Bears Its Own Costs: No fee-shifting was imposed.

Legal Analysis: What the Consent Judgment Signals

Consent judgments in Hatch-Waxman litigation rarely emerge from positions of defendant strength. When a generic challenger agrees to a finding of patent validity and accepts an injunction, it typically signals one or more of the following: that invalidity arguments faced significant evidentiary hurdles, that claim construction rulings disfavored the defendant’s non-infringement positions, or that commercial negotiations produced an agreed launch date more favorable than litigation risk would otherwise yield.

Critically, the consent judgment explicitly preserves FDA authority to grant final approval to Cipla’s ANDA — a standard carve-out ensuring regulatory processes proceed independently of the patent injunction. The dismissal “without prejudice” of invalidity counterclaims preserves the ability to challenge these patents in a different procedural posture, such as an inter partes review (IPR) petition at the USPTO, should commercial circumstances warrant.